Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension

Published:2017-07-07 Issue:11 Volume:19 Page:1620-1624
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Chilton Robert¹^ORCID,Tikkanen Ilkka²³,Hehnke Uwe⁴,Woerle Hans J.⁴,Johansen Odd Erik⁵

Affiliation:

1. Division of Cardiology; University of Texas Health Science Center; San Antonio Texas USA

2. Department of Nephrology, Helsinki University Hospital; University of Helsinki; Helsinki Finland

3. Minerva Institute for Medical Research; Helsinki Finland

4. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

5. Boehringer Ingelheim Norway KS; Asker Norway

Funder

Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12962/fullpdf

Reference18 articles.

1. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes;Heise;Diabetes Obes Metab,2013

2. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial;Barnett;Lancet Diabetes Endocrinol,2014

3. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Häring;Diabetes Care,2013

4. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Häring;Diabetes Care,2014

5. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial;Kovacs;Diabetes Obes Metab,2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications;Biomedicine & Pharmacotherapy;2023-12

2. Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway;Archives of Pharmacal Research;2023-02

3. The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes;Cureus;2023-01-07

4. Research Progress of SGLT2 Inhibitors in the Treatment of Heart Failure Complicated with Atrial Fibrillation;Advances in Clinical Medicine;2023

5. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation;Pharmacological Research;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3